Download PDF
Thromb Haemost 1983; 50(03): 652-655
DOI: 10.1055/s-0038-1665279
Original Article
Schattauer GmbH Stuttgart

Anticoagulant Properties of Three Mucopolysaccharides Used in Rheumatology

F Bauer
The Hemostasis Unit, Geneva University Hospital, and the University Medical Center, Geneva, Switzerland
,
P Schulz
The Hemostasis Unit, Geneva University Hospital, and the University Medical Center, Geneva, Switzerland
,
G Reber
The Hemostasis Unit, Geneva University Hospital, and the University Medical Center, Geneva, Switzerland
,
C A Bouvier
The Hemostasis Unit, Geneva University Hospital, and the University Medical Center, Geneva, Switzerland
› Author Affiliations
Further Information

Publication History

Received 22 September 1982

Accepted 30 June 1983

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Three mucopolysaccharides (MPS) used in the treatment of degenerative joint disease were compared to heparin to establish their relative potencies on 3 coagulation tests, the aPTT, the antifactor X a activity and the dilute thrombin time. One of the compounds, Arteparon®, was one fourth as potent as heparin on the aPTT, but had little or no influence on the 2 other tests. Further in vitro studies suggested that Arteparon® acted at a higher level than factor Xa generation in the intrinsic amplification system and that its effect was independent of antithrombin III. In vivo administration of Arteparon® confirmed its anticoagulant properties, which raises the question of the clinical use of this MPS.

Keywords

Heparin - Other mucopolysaccharides - Anticoagulation - Mode of action
 

  • References

  • 1 Jaques LB. Heparins: anionic polyelectrolyte drugs. Pharmacol Rev 1980; 31: 99-166
    PubMedGoogle Scholar
  • 2 Bach GL, Panse P, Zeiller P. Glykosaminoglykanpolysulfat (GAGS, Arteparon®) zur Basistherapie der Arthrose. Z Rheumatol 1977; 36: 269-274
    PubMedGoogle Scholar
  • 3 Thilo G. Etude de 35 cas d’arthrose traités par l’acide chondroïtine sulfurique. Schweiz Rundschau Med (Praxis) 1977; 66: 1696-1699
    PubMedGoogle Scholar
  • 4 Bjornsson TD, Nash BS, Schaten BS. The anticoagulant effect of chondroitin-4-sulfate. Clin Pharmacol Ther 1982; 31: 203
    PubMedGoogle Scholar
  • 5 Thomas DP, Michalski R, Lane DA, Johnson EA, Kakkar VV. A heparin analogue with specific action on antithrombin III. Lancet 1977; 1: 120-122
    PubMedGoogle Scholar
  • 6 Fischer AM, Barrowcliffe TW, Thomas DP. A comparison of pentosan polysulphate (SP54) and heparin. I: mechanism of action on blood coagulation. Thromb Haemostas 1982; 47: 104-108
    PubMedGoogle Scholar
  • 7 Fischer AM, Merton RE, Marsh NA, Williams S, Gaffney PJ, Barrowcliffe TW, Thomas DP. A comparison of pentosan polysulphate and heparin. II: effects of subcutaneous injection. Thromb Haemostas 1982; 47: 109-113
    PubMedGoogle Scholar
  • 8 Raby C. Un critère d’efficacité des traitements hépariniques. Ann Anesthesiol fr 1964; 5: 129-134
    PubMedGoogle Scholar
  • 9 Milstone JH. A factor in normal human blood which participates in streptococcal fibrinolysis. J Immunol 1941; 48: 109-116
    PubMedGoogle Scholar
  • 10 Flury W. Communiqué de l’OICM. Arteparon, effets non désirables Schweiz Arztz 1982; 63: 1345
    PubMedGoogle Scholar